ArticleJournal of the American Geriatrics Society2025
Disparities in Respiratory Syncytial Virus Vaccine Uptake in the Medicare Fee-for-Service Population During 2023-2024 Season.
Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis.The Lancet regional health. Europe · 2026Article
- Disparities in Respiratory Syncytial Virus Vaccine Uptake in the Medicare Fee-for-Service Population During 2023-2024 Season.Journal of the American Geriatrics Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a common cause of acute respiratory illness and can lead to serious morbidity and mortality in older adults. With the Food and Drug Administration approval and the Centers for Disease Control and Prevention (CDC) recommendation of RSV vaccines in 2023, this study describes first season vaccine uptake in adults ≥ 65 years.
methodsIn a retrospective cohort of 100% Medicare Fee-for-Service (FFS) beneficiaries with Part D coverage, we examined RSV vaccination claims data from July 2023 to June 2024. Cumulative RSV vaccine uptake rates were evaluated by demographic, socioeconomic, and health characteristics, along with evaluation of vaccine coadministration. We reported descriptive statistics.
resultsAmong 15,841,938 Medicare FFS beneficiaries meeting inclusion criteria, 3,330,740 (21.0%) received the RSV vaccine in the first season. Uptake was highest among the 75-84 age group (23.6%) and those with at least one comorbidity (21.8%). Additionally, those with immunocompromising conditions (23.6%) and lung disease (21.3%) had the highest uptake. The lowest uptake was observed among beneficiaries ≥ 85 years (17.1%), beneficiaries with three or more comorbidities, (19.4%) and those in the southern census region (19.3%). The lowest uptake according to comorbidity status were those with liver disorders (17.1%) and neurologic or neuromuscular conditions (17.8%). Disparities were observed with only 6.8% of Hispanic, 12.6% of Black, 9.3% of those with a low-income subsidy (LIS), and 9.0% of dual Medicare-Medicaid eligible beneficiaries receiving the vaccine. Coadministration occurred in 38.4% of RSV vaccinations.
conclusionsVaccination to prevent RSV disease began during the 2023-2024 season where less than a quarter of the Medicare FFS population was vaccinated. Disparities in uptake were observed by race and ethnicity, socioeconomic status, geography, comorbidity status, and by age group. These results highlight the need for more targeted public health efforts to improve vaccination among those at high risk for severe RSV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.